Senior Vice President, Life Science Pathology, Tempus
Dr. Nike Beaubier serves as Senior Vice President, Life Science Pathology at Tempus. Dr. Beaubier most recently served as Medical Director of the Diagnostic Molecular Biology Laboratory at Northwestern Memorial Hospital and Assistant Professor of Pathology at Northwestern University Feinberg School of Medicine. She earned a bachelor’s degree in molecular biology from the University of Texas, Austin, a master of science from Stanford University and her medical degree from Columbia University. She completed an Anatomic Pathology residency, followed by a Molecular Genetic Pathology Fellowship at Columbia, then a Gastrointestinal/Surgical Pathology Fellowship at Northwestern University.
Director, Liquid Biopsy Laboratory; Research Assistant Professor, Department of Medicine, Division of Hematology/Oncology, University of Pennsylvania
Erica L. Carpenter, MBA, PhD, is the director of the Liquid Biopsy Laboratory and a Research Assistant Professor in the Department of Medicine, Division of Hematology/Oncology at the University of Pennsylvania.
She completed her doctoral studies in the Immunology program of the Biomedical Graduate Studies program at the University of Pennsylvania School of Medicine. She subsequently completed post-doctoral training in the field of cancer genetics at the Oncology Division of the Children’s Hospital of Philadelphia.
Prior to completing her studies in medical science, Dr. Carpenter obtained a Masters in Business Administration at the Tuck School at Dartmouth College, and worked as a business executive for a Fortune 50 manufacturer. Over the course of her business career, she had profit and loss responsibility for divisions with revenues up to $2 billion, and participated in the management of both domestic and overseas business units.
Dr. Carpenter’s NCI-funded research programs focus on the identification, capture, and analysis of circulating tumor cells, exosomes, and cell-free circulating tumor DNA from cancer patients. Capture and molecular characterization of such circulating tumor material from cancer patient blood samples is a rapidly expanding area of translational medicine which allows for: 1) early detection of disease as well as post-therapy monitoring of minimal residual disease, 2) an efficient means of determining clinical and biological response to therapy and, thus, clinical decision making, and, 3) cancer genetic phenotyping to drive personalized medicine that obviates the need for serial biopsies in a population of patients for whom such invasive procedures are difficult, risky, and insufficient. The overarching goal of Dr. Carpenter’s research is to utilize molecular profiling of circulating tumor material to improve the delivery of precision medicine by informing individualized treatment decisions, and targeting the most aggressive cancer cells. For our patients, this means better care and less discomfort.
Vice President, Early Clinical Development, Foundation Medicine
David Fabrizio serves as the Vice President of Early Clinical Development at Foundation Medicine in Cambridge, MA. Under Mr. Fabrizio’s leadership, Foundation Medicine has pioneered new genomic biomarkers for immunotherapy, including tumor mutational burden (TMB), and launched the first comprehensive genomic profiling test approved by the FDA, FoundationOne CDx. Mr. Fabrizio also led the development of the first blood-based assay to determine immunotherapy response, published in Nature Medicine, which was also selected as one of Nature’s most notable advances of 2018. He holds ten different patents or patent applications for therapeutic and diagnostic methods for cancer, as well as over 30 publications in peer reviewed journals including Nature, Cell, The Lancet, and the Journal of American Medical Association (JAMA), and is a member of ASCO and AACR.
Medical Director, Oncology/Hematology, Cancer Center of Sarasota-Manatee
Steven W. Mamus, MD, is a prominent medical oncologist specializing in the treatment of cancer and blood-related disorders. Dr. Mamus serves as Medical Director of Oncology/Hematology at the Cancer Center of Sarasota, which he founded in 2006 to bring patient-centric care and academic medical expertise to patients. Dr. Mamus also played a key part in the development of MD Anderson Cancer Center Orlando, where he served as chief of medical oncology. Dr. Mamus is nationally recognized with a lengthy list of honors as a physician, clinical research expert, and educator, including being named a top physician by Best Doctors in America. He has been an investigator in over 100 clinical trials involving diverse therapies. Dr. Mamus is board certified in Medical Oncology, Hematology, and Internal Medicine. He is a member of the American Medical Association, Florida Medical Association, American Society of Hematology, and the American Society of Clinical Oncology.
Professor of Oncology, Johns Hopkins University School of Medicine
Co-Director, Cancer Genetics and Epigenetics, Sidney Kimmel Cancer Center
Founder, Delfi Diagnostics
Dr. Velculescu led the first genome-wide sequence analysis in human cancers, identifying key genes and pathways dysregulated in tumorigenesis. He developed methods for global gene expression analyses and coined the word “transcriptome” to describe the patterns that could now obtained in cancer and other cells. This research has revealed the genomic landscape of human cancers, including in breast, colorectal, brain, pancreatic, ovarian, head and neck, and lung cancers. These analyses identified a variety of genes not previously known to be involved in neoplasia, including PIK3CA as one of the most highly mutated genes in human cancer. His team’s discoveries have led to new FDA approved therapies against PI3K (alpelisib) and IDH1 (ivosidenib), and diagnostic tests for comprehensive tumor profiling. More recently, his group has invented non-invasive liquid biopsy approaches for early detection and monitoring of cancer patients. His work has created the foundation of precision oncology and has benefited patients worldwide.
Dr. Velculescu currently serves as Professor of Oncology, Pathology, and Medicine, and Genetic Medicine and is the Co-Director of Cancer Genetics and Epigenetics at the Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University School of Medicine. Dr. Velculescu attended Stanford University, where he graduated with Honors and Distinction in Biological Sciences. He obtained his M.D. and Ph.D. in Human Genetics and Molecular Biology at the Johns Hopkins University School of Medicine.
Dr. Velculescu has served as a member of the Board of Directors of the American Association of Cancer Research (AACR) and as a member of scientific advisory boards of Dana Farber / Harvard Cancer Center, Cancer Research UK, Tisch Cancer Center at Mount Sinai, Ludwig Cancer Research, the Mark Foundation for Cancer Research, and the White House Cancer Moonshot effort. He is a founder of Personal Genome Diagnostics and Delfi Diagnostics. His work has been recognized by a variety of national and international awards and honors, including the Grand Prize Winner of the Amersham/Pharmacia & Science Young Scientist Prize (1999), Judson Daland Prize of the American Philosophical Society (2008), the European Association of Cancer Research and Carcinogenesis Young Investigator Award (2008), the AACR Award for Outstanding Achievement in Cancer Research (2009), the Paul Marks Prize for Cancer Research (2011), the EY Entrepreneur of the Year Award for Maryland (2016), and the AACR Team Science Awards for Research in Pancreatic Cancer (2013), Brain Cancer (2014), and Liquid Biopsies (2017), and he has been elected as a Fellow of the AACR Academy (2022). Dr. Velculescu’s publications have been cited more than 100,000 times and he has been recognized by Thomson Reuters as among the most highly cited scientists in the world.